- Email: [email protected]
4885236 Method for determining tissue of origin and presence and extent of cellular abnormalities
xxvi
New Patents
toxic/antibodies) is separated, thereby providing a significant quantity of scarce serum inexpensively.
I anitgen is incubated in the presence of milk proteins.
4885236 4885172 COMPOSITION FOR TARGETING, STORING AND LOADING OF LIPOSOMES Marcel B Bally, Helen Loughrey, Pieter R Cullis, Vancouver, Canada assigned to The Liposome Company Inc The present invention describes a composition consisting of liposomes covalently or noncovalently coupled to the glycoprotein streptavidin. The streptavidin may additionally be coupled to biotinated proteins such as Immunoglobulin G or monoclonal antibodies. The liposomes of the invention may have a transmembrane potential across their membranes, and may be dehydrated. In addition, the composition may contain ionizable bioactive agents such as antineoplastic agents, and may be used in diagnostic assays.
4885235 METHOD FOR RAPID AND SENSITIVE DETECTION OF HIV-1 ANTIBODIES Kurt Osther, Louis Dyll assigned to 501 BioResearch Laboratories Inc A rapid and sensitive assay method for the detection of antibodies to Human T-Cell Leukemia Virus-llI (HIV-I), the AIDS virus, and diagnostic test kits for carrying out method. According to the method of the invention, which is referred to as a Quick Western Blot II or Rapid Western Blot, electrophoretically resolved HIV-
METHOD FOR DETERMINING TISSUE OF ORIGIN AND PRESENCE AND EXTENT OF CELLULAR ABNORMALITIES Sheldo Penman, Edward G Fey assigned to Massachusetts Institute of Technology A biochemical procedure for identification and characterization of cells in a biopsy or sample of a body fluid. The method can be used to determine cell type, i.e. epidermal, neuronal; tissue of origin, i.e. breast tissue, liver tissue; and degree of abnormality. The procedure can also be used to make antibodies and hybridization probes to detect cell or tissue specific antigens and nuclear matrix associated nucleic acids in cellular material and body fluids. The procedure is based on the isolation and analysis of the components of a specific subcellular protein fraction referred to here as the nuclear matrix. The nuclear matrix includes proteins and nuclear matrix associated D N A specific to different cell types. These proteins and nucleic acids are altered or new ones expressed as a result of viral infection, genetic defects or malignancy. The method has a number of important clinical applications in determining tissue type, tissue of origin, degree of malignancy and extent of metastasis in cancer patients; in detecting and analyzing chromosomal deficiencies or genetic defects, especially in cells obtained by amniocentesis; in identifying viral or other infections; and in measuring the extent and location of cell damage, particularly in patients with localized having molecular weights of 140 K D and 105 KD under reducing conditions and 120 K D and 90 K D under non-reducing conditions, antibodies against this antigen, and a method of using these antibodies to activate T-cells. The antibodies are able to induce T-cell activation in synergy with phorbol myristate acetate alone and with antibody against the T 113 epitope o f t I I (CD2) antigen alone.
New Patents
toxic/antibodies) is separated, thereby providing a significant quantity of scarce serum inexpensively.
I anitgen is incubated in the presence of milk proteins.
4885236 4885172 COMPOSITION FOR TARGETING, STORING AND LOADING OF LIPOSOMES Marcel B Bally, Helen Loughrey, Pieter R Cullis, Vancouver, Canada assigned to The Liposome Company Inc The present invention describes a composition consisting of liposomes covalently or noncovalently coupled to the glycoprotein streptavidin. The streptavidin may additionally be coupled to biotinated proteins such as Immunoglobulin G or monoclonal antibodies. The liposomes of the invention may have a transmembrane potential across their membranes, and may be dehydrated. In addition, the composition may contain ionizable bioactive agents such as antineoplastic agents, and may be used in diagnostic assays.
4885235 METHOD FOR RAPID AND SENSITIVE DETECTION OF HIV-1 ANTIBODIES Kurt Osther, Louis Dyll assigned to 501 BioResearch Laboratories Inc A rapid and sensitive assay method for the detection of antibodies to Human T-Cell Leukemia Virus-llI (HIV-I), the AIDS virus, and diagnostic test kits for carrying out method. According to the method of the invention, which is referred to as a Quick Western Blot II or Rapid Western Blot, electrophoretically resolved HIV-
METHOD FOR DETERMINING TISSUE OF ORIGIN AND PRESENCE AND EXTENT OF CELLULAR ABNORMALITIES Sheldo Penman, Edward G Fey assigned to Massachusetts Institute of Technology A biochemical procedure for identification and characterization of cells in a biopsy or sample of a body fluid. The method can be used to determine cell type, i.e. epidermal, neuronal; tissue of origin, i.e. breast tissue, liver tissue; and degree of abnormality. The procedure can also be used to make antibodies and hybridization probes to detect cell or tissue specific antigens and nuclear matrix associated nucleic acids in cellular material and body fluids. The procedure is based on the isolation and analysis of the components of a specific subcellular protein fraction referred to here as the nuclear matrix. The nuclear matrix includes proteins and nuclear matrix associated D N A specific to different cell types. These proteins and nucleic acids are altered or new ones expressed as a result of viral infection, genetic defects or malignancy. The method has a number of important clinical applications in determining tissue type, tissue of origin, degree of malignancy and extent of metastasis in cancer patients; in detecting and analyzing chromosomal deficiencies or genetic defects, especially in cells obtained by amniocentesis; in identifying viral or other infections; and in measuring the extent and location of cell damage, particularly in patients with localized having molecular weights of 140 K D and 105 KD under reducing conditions and 120 K D and 90 K D under non-reducing conditions, antibodies against this antigen, and a method of using these antibodies to activate T-cells. The antibodies are able to induce T-cell activation in synergy with phorbol myristate acetate alone and with antibody against the T 113 epitope o f t I I (CD2) antigen alone.